REG - Synairgen plc - Synairgen Presents SNG001 Data at ESWI

SynairgenAnnouncement

06/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211206:nRSF5997Ua&default-theme=true

RNS Number : 5997U  Synairgen plc  06 December 2021

 

Press Release

 

Synairgen plc

('Synairgen' or the 'Company')

Synairgen to Present Clinical and in vitro Data on the Antiviral Activity of
SNG001 at the 8(th) ESWI Influenza Conference

 

Southampton, UK - 6 December 2021: Synairgen plc (LSE: SNG), the respiratory
company developing SNG001, a formulation for inhalation containing the
broad-spectrum antiviral protein interferon beta for the treatment of severe
viral lung infections, announced today an oral presentation and a poster
presentation at the 8(th) European Scientific Working Group in Influenza
(ESWI) Influenza Conference, which is taking place virtually from 4-7 December
2021.

The oral presentation will highlight clinical data demonstrating the antiviral
activity of SNG001 in the lungs of patients with asthma and those with chronic
obstructive pulmonary disease (COPD).

The poster presentation will highlight in vitro data showing the antiviral
activity of SNG001 against Alpha, Beta and Gamma SARS-CoV-2 variants.

Details of the presentations are as follows:

Oral Presentation:

Title:               Local delivery of interferon beta (SNG001)
by inhalation upregulates lung antiviral biomarkers

Presenter:      Phillip D Monk, Ph.D., Chief Scientific Officer, Synairgen

Abstract:        270

Date/Time:     6 December 2021; 17:00-18:45 GMT

Track:             Scientific Programme

Poster Presentation:

Title:               Interferon beta has potent antiviral
activity against SARS-CoV-2 including variants of concern

Abstract:        269

Date/Time:     On-demand

 

This announcement contains inside information for the purposes of Article 7 of
Regulation (EU) No. 596/2014 ('MAR').

 

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Chief Financial Officer

Brooke Clarke, Head of Communications

Brooke.Clarke@synairgen.com (mailto:Brooke.Clarke@synairgen.com)

Tel: + 44 (0) 23 8051 2800

Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott, Jessica Hodgson, Lucy Featherstone

synairgen@consilium-comms.com (mailto:synairgen@consilium-comms.com)

Tel: +44 (0) 20 3709 5700

MKC STRATEGIES, LLC (US Media Relations)

Mary Conway

MConway@MKCStrategies.com (mailto:MConway@MKCStrategies.com)

Tel: +1 516-606-6545

 

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery,
development and commercialisation. The Company's primary focus is developing
SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially
the first host-targeted, broad-spectrum antiviral treatment delivered directly
into the lungs. SNG001 has been granted Fast Track status from the US Food and
Drug Administration (FDA) and the Phase 3 SPRINTER trial was deemed an Urgent
Public Health study by the UK's National Institute for Health Research (NIHR).
Synairgen's Phase 3 clinical programme is currently evaluating nebulised
SNG001 in patients across 17 countries. In a Phase 2 trial in hospitalised
COVID-19 patients, SNG001 demonstrated a greater than two-fold chance of
recovery to 'no limitation of activities' versus placebo.(1)

Founded by University of Southampton Professors Sir Stephen Holgate, Donna
Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG).
For more information about Synairgen, please see www.synairgen.com
(http://www.synairgen.com) .

(1)https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext
(https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext)
 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUVOURAWUURUA